Author: Williams, Sophie Therese; El Badri, Salma; Hussain, Syed Anwer
Title: Urological cancer patients receiving treatment during COVID-19: a single-centre perspective Cord-id: mixpcamx Document date: 2021_2_8
ID: mixpcamx
Snippet: BACKGROUND: Active cancer, immunosuppressive treatments and immunotherapies have been reported to increase cancer patients’ risk of developing severe COVID-19 infection. For patients and clinicians, treatment risk must be weighed against disease progression. METHODS: This retrospective case series surveys urological cancer patients who made informed decisions to continue anticancer treatment (ACT) at one centre from March to June 2020. RESULTS: Sixty-one patients (44 bladder, 10 prostate, 7 up
Document: BACKGROUND: Active cancer, immunosuppressive treatments and immunotherapies have been reported to increase cancer patients’ risk of developing severe COVID-19 infection. For patients and clinicians, treatment risk must be weighed against disease progression. METHODS: This retrospective case series surveys urological cancer patients who made informed decisions to continue anticancer treatment (ACT) at one centre from March to June 2020. RESULTS: Sixty-one patients (44 bladder, 10 prostate, 7 upper urinary tract cancers) received 195 cycles of ACT (99 chemotherapy, 59 immunotherapy, 37 as part of ongoing clinical trials), with a range of indications: 43 palliative, 10 neoadjuvant, 8 adjuvant. One patient tested positive for COVID-19 but experienced only mild symptoms. Fourteen patients interrupted treatment outside of their schedule, seven of these due to potential COVID-19 associated risk. ACT supportive steroids were not associated with higher rates of COVID-19. CONCLUSIONS: This single-centre series reports that ACT administration did not result in an apparent excess in symptomatic COVID-19 infections.
Search related documents:
Co phrase search for related documents- absence presence and additional seven: 1
- absence presence and lymph node: 1, 2, 3, 4, 5
- active cancer and acute respiratory: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34
- active cancer and adjuvant chemotherapy: 1, 2
- active cancer and admission test: 1
- active cancer and lymph node: 1, 2
- acute respiratory and additional seven: 1, 2, 3, 4
- acute respiratory and adjuvant chemotherapy: 1, 2
- acute respiratory and admission test: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40
- acute respiratory and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41
- additional seven and adjuvant chemotherapy: 1
- adjuvant chemotherapy and lymph node: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
Co phrase search for related documents, hyperlinks ordered by date